Association of APOA1 and APOA5 polymorphisms and haplotypes with lipid parameters in a Brazilian elderly cohort by Furuya, Tatiane Katsue et al.
©FUNPEC-RP www.funpecrp.com.brGenetics and Molecular Research 12 (3): 3495-3499 (2013)
Short Communication
Association of APOA1 and APOA5 
polymorphisms and haplotypes with lipid 
parameters in a Brazilian elderly cohort
T.K. Furuya1, E.S. Chen1, V.K. Ota1, D.R. Mazzotti1, L.R. Ramos2,
M.S. Cendoroglo2, L.Q. Araujo2, R.R. Burbano1 and M.A.C. Smith1
1Disciplina de Genética, Departamento de Morfologia e Genética,
Universidade Federal de São Paulo, São Paulo, SP, Brasil
2Disciplina de Geriatria e Gerontologia, Departamento de Medicina, 
Universidade Federal de São Paulo, São Paulo, SP, Brasil
Corresponding author: M.A.C. Smith
E-mail: tuty_furuya@yahoo.com.br
Genet. Mol. Res. 12 (3): 3495-3499 (2013)
Received July 11, 2012
Accepted November 10, 2012
Published February 28, 2013
DOI http://dx.doi.org/10.4238/2013.February.28.7
ABSTRACT. Apolipoproteins have an important role in lipid 
metabolism and transport. Polymorphisms in the APOA1/C3/A4/
A5 gene cluster have been associated with lipid alterations and 
cardiovascular diseases. We investigated APOA1 XmnI, APOA5 
S19W, and APOA5 -1131T>C polymorphisms in 377 individuals from 
a cohort of a longitudinal Brazilian elderly study. Allele frequencies, 
genotype distribution, and association with major morbidities as well 
as with lipids, creatinine, albumin, urea, glycated hemoglobin, and 
fasting glucose serum levels were investigated. Linkage disequilibrium 
and haplotype associations were also analyzed. This is the first time 
that haplotypes involving these polymorphisms were evaluated. 
Genotyping was performed by PCR-RFLP. Minor allele frequencies 
were 0.119, 0.071, and 0.158 for XmnI, S19W, and -1131T>C 
polymorphisms, respectively. We found a significant association of the 
-1131C allele with low LDL-C levels. We also observed that XmnI 
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and S19W polymorphisms were in linkage disequilibrium. The C/G 
haplotype, which is composed of the wild-type allele of XmnI and the 
minor allele of S19W, was associated with high total cholesterol serum 
levels in this elderly population. We conclude that the -1131T>C 
polymorphism and the C/G haplotype, including XmnI and S19W 
polymorphisms, are associated with alterations in lipid levels and may 
be risk factors for cardiovascular disease in the Brazilian elderly.
Key words: APOA1/A5 polymorphisms; Apolipoproteins; Haplotypes;
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INTRODUCTION
Alterations in lipid metabolism are highly associated with cardiovascular diseases 
(CVD). Elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C) and 
triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels are deter-
minant risk factors for CVD (Hamon et al., 2006; Andrade et al., 2010). In 2009, three gen-
ome-wide association studies described new loci associated with serum lipid levels, including 
the APOA1/C3/A4/A5 gene cluster, located on 11q23 (Aulchenko et al., 2009; Kathiresan et 
al., 2009; Sabatti et al., 2009).
APOA1 is the main apolipoprotein component of HDL-C, and an inverse relation-
ship between HDL-C and APOA1 concentrations and risk for premature atherosclerosis has 
been reported (Srivastava and Srivastava, 2000). APOA5, another apolipoprotein, has been 
reported to be an important regulator of TG levels (Hubacek et al., 2004). Polymorphisms in 
APOA1 and APOA5 genes have been associated with lipid alterations and CVD (Hubacek et 
al., 2004; de Andrade et al., 2011).
We aimed to determine the allelic frequencies of three well-described single nucleo-
tide polymorphisms (SNPs), namely APOA1 XmnI (rs11216158), APOA5 S19W (rs3135506), 
and APOA5 -1131T>C (rs662799), as well as to investigate the association of these SNPs and 
their haplotypes with the morbidities (CVD, hypertension, type II diabetes, obesity, depres-
sion, and dementia) affecting an elderly Brazilian cohort and with serum levels of TG, total 
cholesterol, HDL-C, very low-density lipoprotein cholesterol, LDL-C, creatinine, urea, albu-
min, glycated hemoglobin, and fasting glucose.
MATERIAL AND METHODS
The population studied was a subsample of 377 subjects (257 females and 120 males) 
who participated in wave 4 (2000-2001) of the Elderly Longitudinal Study (EPIDOSO) (Ra-
mos et al., 1998). Table 1 summarizes the characteristics of our sample. This population had a 
mean age of 79.76 ± 5.29 years (range 66-97 years) and was composed of individuals of Eu-
ropean (89.2%), Japanese (3.3%), Middle Eastern (1.8%), and mixed or other (5.7%) origins. 
The Institutional Research Ethics Committee approved this study, and all participants or their 
representatives gave informed consent according to the Declaration of Helsinki. All clinical 
characterization of our sample, laboratory tests, and DNA extraction have been previously 
described (Chen et al., 2010).
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For APOA1 XmnI polymorphism, a 331-bp fragment was amplified us-
ing the primers: forward: 5ꞌ-AGACGAGGGAAAGAAATGGGTGGA-3ꞌ and reverse: 
5ꞌ-TGAACAGCATCTTACCAAGCAGGCA-3ꞌ. Primers used for the APOA5 S19W poly-
morphism amplification were previously described (Pennacchio et al., 2002). PCR cycling 
conditions were 5 min at 94°C, followed by 35 cycles of 94°C for 30 s, 60°C (XmnI) or 69°C 
(S19W) for 30 s, and 72°C for 45 s, and a final extension at 72°C for 7 min. PCR products 
were digested with 5 U XmnI or 7.5 U EagI (New England Biolabs) at 37°C for 16 h for XmnI 
and S19W polymorphisms, respectively. APOA5 -1131T>C genotyping was performed as de-
scribed by Chen et al. (2006). 
Descriptive statistics, logistic regression analysis, the χ2 test, and the Student t-test 
were used. Linkage disequilibrium and haplotype association analyses were also performed. 
Details of the statistical analyses were described in our previous report (Chen et al., 2010).
RESULTS AND DISCUSSION
Minor allele frequencies were 0.119, 0.071, and 0.158 for XmnI, S19W, and -1131T>C 
polymorphisms, respectively. The -1131T>C polymorphism deviated from Hardy-Weinberg 
equilibrium (P < 0.05) and was not included in the haplotype analysis.
We did not find any associations of XmnI and S19W polymorphisms either with the 
serum lipid and protein analyzed or with the morbidities studied, in agreement with studies in 
other populations (Marcil et al., 1996; Martinelli et al., 2007). However, associations of the 
T allele of the XmnI polymorphism with increased TG, total cholesterol, and LDL-C levels 
have been described (Dallinga-Thie et al., 1996; Hong et al., 1997). Regarding the S19W 
polymorphism, the G allele has been associated with higher plasma TG in several populations 
(Hubacek et al., 2004; Martinelli et al., 2007), as well as in another population from the South 
Brazil region (de Andrade et al., 2011). These controversial findings may be due to the hetero-
geneity of the study populations and to their different ethnic backgrounds.
Variables N Number of affected individuals (%) Means ± SD
Age (years) 377  79.76 ± 5.29
Gender 377 257 ♀ (68.2%)/120 ♂ (31.8%)
Cardiovascular disease 377   83 (22.0%)
Type II diabetes 376 240 (63.8%)
Hypertension 375 313 (83.5%)
Obesity 303 124 (40.9%)
Depression 349   69 (19.8%)
Dementia 370 39 (8.1%)
Total cholesterol (mg/dL) 243  216.12 ± 42.23
Triglyceride (mg/dL) 243  150.06 ± 71.58
VLDL cholesterol (mg/dL) 237    28.67 ± 11.29
HDL cholesterol (mg/dL) 242    54.28 ± 13.89
LDL cholesterol (mg/dL) 235  132.05 ± 35.84
Urea (mg/dL) 235    40.36 ± 12.61
Creatinine (mg/dL) 234    0.95 ± 0.24
Albumin (g/dL) 234    4.04 ± 0.33
Glycated hemoglobin (%) 335    5.78 ± 1.48
Fasting glucose (mg/dL) 344    99.18 ± 32.37
Table 1. Age, gender, serum levels, and morbidities affecting the sample studied of an Brazilian elderly cohort.
N = number of consulted individuals; SD = standard deviation; VLDL = very-low density lipoprotein.
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Our data showed that XmnI and S19W polymorphisms were in linkage disequilibrium 
(r2 = 0.042; Dꞌ = 0.2908; P = 0.001). Upon analyzing the haplotypes, we found that the C/G 
haplotype, which is composed of the wild-type allele of XmnI and the minor allele of S19W, 
respectively, was associated with higher serum total cholesterol levels (P = 0.048) compared to 
the C/C haplotype, which includes the wild-type alleles for both polymorphisms. Although this 
borderline association had a small effect, it must be considered since these findings suggest a 
synergistic effect of these SNPs on serum cholesterol levels. Hamon et al. (2006) showed that 
multiple SNPs within the APOA1/C3/A4/A5 gene cluster did not have significant genotype 
effects when separately considered, but when combined to define two-SNP genotypes, they 
had significant effects on total cholesterol levels. Haplotype analyses can therefore provide 
additional information compared to the single SNP analyses, which may result in an under-
estimated contribution of genetic variation to changes in quantitative CVD risk factor traits.
Concerning the -1131T>C polymorphism, a previous study from our group did not 
show an association between C allele and morbidities (Chen et al., 2006). On the other hand, 
the present study found that C allele carriers [mean = 124.49; standard deviation (SD) = 39.86] 
showed lower LDL-C levels than did T allele carriers (mean = 133.56; SD = 36.20; P = 0.036). 
It has been shown that elevated LDL-C levels are strongly related to CVD (Andrade et al., 
2010), suggesting that this polymorphism might act as a protective factor against CVD.
In conclusion, our study showed a significant association of the -1131C allele with 
lower LDL-C levels and of the C/G haplotype, concerning the XmnI and S19W polymor-
phisms, with higher serum total cholesterol levels in a Brazilian elderly cohort. Caution must 
be taken at this time in interpreting these results, which need to be confirmed with studies in 
larger populations. Nonetheless, these data may lead to a better understanding on how genetic 
factors contribute to changes in serum lipid levels and may modify CVD risk in the Brazilian 
elderly population.
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